Resumen

Introduction: Arylamine N-acetyltransferase-2 (NAT-2) is a key human enzyme in drug detoxification and elimination. Mutations in NAT-2 affect the activity of anti-tuberculosis drugs and result in three different phenotypes: rapid (RA), intermediate (IA) and slow acetylators (SA). Methodology: The allelic, genotypic and phenotypic frequencies of NAT-2 were studied in 185 patients from Buenos Aires by restriction fragment length polymorphism. Conclusion: A high prevalence of SA might have an impact on anti-TB drug-induced hepatotoxicity.

Palabras clave: NAT-2; polymorphism; tuberculosis; acetylator profile; prevalence.

2012-09-26   |   506 visitas   |   Evalua este artículo 0 valoraciones

Vol. 6 Núm.9. Septiembre 2012 Pags. 671-674 J Infect Developing Countries 2012; 6(9)